e-Therapeutics enters drug discovery partnership with Cresset BioMolecular Discovery

27 January 2009

e-Therapeutics plc (AIM: ETX), a drug discovery and development company, has entered into an agreement with UK-based Cresset BioMolecular Discovery Ltd, a specialist in molecular field technology.

The initial focus of the collaboration will combine e-Therapeutics’ world-leading computational platform, which identifies the impact of drug compounds on cells, with Cresset’s advanced technology in chemical comparison, to deliver powerful drug de-risking and repositioning capabilities. The first project to be undertaken will be on pain treatment, which remains  an area of significant unmet medical need.

Cresset has pioneered a ‘molecular fields’ approach to computational drug discovery which summarises key binding features and explains how active compounds with  different structures can interact in a similar way with a protein active site. The combination of this platform with e-Therapeutics’ analysis technology to assess the efficacy, safety and tolerance of drug candidates will enable the collaboration to significantly enhance the companies’ screening and de-risking capabilities.

Beatrice Leigh, CEO of Cresset BioMolecular Discovery said: “With this partnership, we are now perfectly positioned to begin in-house drug discovery and development programmes. We are excited to be working with e-Therapeutics in this way and look forward to using our combined expertise to generate safer, more effective medicines”.

Professor Malcolm Young, CEO of e-Therapeutics, said: “This drug discovery partnership brings together two technology companies with complementary expertise, both at the forefront of their respective fields. We expect that this strong research and development partnership will lead to the development of promising new chemical entities and repositioned drugs across a wide range of therapeutic areas.”

Bookmark this page

To top